Skip to main content
    O

    Ocugen Inc (OCGN)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.77
    -0.05 (-6.62%)

    Market Cap: $280.88M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Ocugen Inc (OCGN) Earnings: Report Dates and Results

    Updated Nov 4, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Ocugen (OCGN) is expected to report earnings on Mar 2, 2027. In the quarter ended Sep 30, 2026, Ocugen reported EPS of -$0.06, in line with the -$0.06 estimate. It beat the EPS estimate in 3 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    34%(13/38)
    Avg Surprise
    -86.42%

    Upcoming Estimates

    Reports Mar 2, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus-$0.06
    Range-$0.07 - -$0.04
    8 analysts
    Revenue Consensus
    $1.71M
    RangeN/A
    8 analysts
    Reports May 3, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus-$0.07
    Range-$0.08 - -$0.06
    3 analysts
    EPS RevisionsNo revisions (30d)
    EPS Estimate DriftChange to current
    90d ago-$0.08+12.5%
    60d ago-$0.08+12.5%
    30d ago-$0.08+12.5%
    7d ago-$0.08+12.5%
    Current-$0.07
    Revenue Consensus
    $1.10M
    Range$1.00M - $1.20M
    2 analysts

    Next Report

    OCGN has an expected report date of Mar 2, 2027.

    OCGN Earnings Call

    The latest OCGN earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 38 quarters below that had an estimate, OCGN beat 13, missed 20 and matched 5. Revenue for the quarter ended Sep 30, 2026 was $1.95M, up 11.4% from $1.75M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026-$0.06-$0.06-$0.07 - -$0.040.00%In lineN/A30 up, 0 downNov 4, 2026$1.95M
    Jun 30, 2026-$0.07-$0.05-$0.06 - -$0.04-40.00%MissN/A52 up, 3 downAug 6, 2026$1.49M
    Mar 31, 2026-$0.06-$0.05-$0.06 - -$0.05-20.00%MissN/A61 up, 0 downMay 5, 2026$1.53M
    Dec 31, 2025-$0.06-$0.06-$0.06 - -$0.05-7.14%MissN/A40 up, 0 downMar 4, 2026N/A
    Sep 30, 2025-$0.07-$0.06-$0.07 - -$0.05-16.67%MissN/A40 up, 0 downNov 5, 2025$1.75M
    Jun 30, 2025-$0.05-$0.06-$0.06 - -$0.05+16.67%BeatN/A30 up, 0 downAug 1, 2025$1.37M
    Mar 31, 2025-$0.05-$0.06-$0.07 - -$0.05+16.67%BeatN/A30 up, 0 downMay 9, 2025$1.48M
    Dec 31, 2024-$0.05-$0.05-$0.06 - -$0.04+6.19%BeatN/A31 up, 0 downMar 5, 2025$764000
    Sep 30, 2024-$0.05-$0.05-$0.07 - -$0.050.00%In lineN/A30 up, 1 downNov 8, 2024$1.14M
    Jun 30, 2024-$0.04-$0.05-$0.06 - -$0.05+20.00%BeatN/A30 up, 0 downAug 8, 2024$1.14M
    Mar 31, 2024-$0.05-$0.06-$0.07 - -$0.06+16.67%BeatN/A30 up, 0 downMay 13, 2024$1.01M
    Dec 31, 2023-$0.03-$0.06-$0.07 - -$0.06+50.00%BeatN/A20 up, 0 downMar 26, 2024$1.41M
    Sep 30, 2023-$0.06-$0.07-$0.07 - -$0.07+14.29%BeatN/A40 up, 0 downNov 9, 2023$3.70M
    Jun 30, 2023-$0.10-$0.07-$0.08 - -$0.07-42.86%MissN/A30 up, 0 downAug 21, 2023$485000
    Mar 31, 2023-$0.07-$0.11-$0.11 - -$0.10+36.36%BeatN/A50 up, 0 downMay 5, 2023$443000
    Dec 31, 2022-$0.10-$0.10-$0.11 - -$0.060.00%In lineN/A50 up, 0 downFeb 28, 2023$2.49M
    Sep 30, 2022-$0.10-$0.10-$0.12 - -$0.060.00%In lineN/A60 up, 0 downNov 8, 2022N/A
    Jun 30, 2022-$0.09-$0.08-$0.10 - -$0.06-12.50%MissN/A50 up, 0 downAug 5, 2022N/A
    Mar 31, 2022-$0.09$0.01-$0.07 - $0.17-776.69%MissN/A40 up, 0 downMay 6, 2022N/A
    Dec 31, 2021-$0.07-$0.07-$0.12 - -$0.030.00%In lineN/A4N/AFeb 25, 2022N/A
    Sep 30, 2021-$0.05-$0.04-$0.04 - -$0.04-25.00%MissN/A40 up, 0 downNov 9, 2021N/A
    Jun 30, 2021-$0.13-$0.03-$0.04 - -$0.02-333.33%MissN/A4N/AAug 6, 2021N/A
    Mar 31, 2021-$0.04$0.40-$0.02 - $1.01-110.00%MissN/A2N/AMay 7, 2021N/A
    Dec 31, 2020-$0.03-$0.02-$0.02 - -$0.02-50.00%Miss-100.7%4N/AMar 18, 2021$42.58M
    Sep 30, 2020-$0.07-$0.02-$0.02 - -$0.02-250.00%MissN/A3N/ANov 6, 2020N/A
    Jun 30, 2020-$0.19-$0.04-$0.04 - -$0.03-375.00%MissN/A2N/AAug 14, 2020$43000
    Mar 31, 2020-$0.07-$0.05-$0.05 - -$0.05-40.00%MissN/A1N/AMay 8, 2020N/A
    Dec 31, 2019$4.13-$0.14N/AN/AN/AN/AN/AN/AMar 27, 2020N/A
    Sep 30, 2019-$3.55-$0.60N/A-491.67%MissN/AN/AN/ANov 12, 2019N/A
    Jun 30, 2019-$0.12-$0.01N/AN/AN/AN/AN/AN/AAug 9, 2019N/A
    Mar 31, 2019-$4.80-$0.60N/A-700.00%MissN/AN/AN/AMay 15, 2019N/A
    Dec 31, 2018-$6.60-$3.60N/A-83.33%MissN/AN/AN/AMar 22, 2019N/A
    Sep 30, 2018-$14.40-$12.20N/A-18.03%MissN/AN/AN/ANov 8, 2018N/A
    Jun 30, 2018-$7.80-$14.00N/A+44.29%BeatN/AN/AN/AAug 9, 2018N/A
    Mar 31, 2018-$31.20-$13.20N/A-136.36%MissN/AN/AN/AMay 10, 2018N/A
    Dec 31, 2017-$15.60-$16.20N/A+3.70%BeatN/AN/AN/AMar 15, 2018N/A
    Sep 30, 2017-$13.80-$16.92N/A+18.44%BeatN/AN/AN/ANov 9, 2017N/A
    Jun 30, 2017-$15.00-$18.15N/A+17.36%BeatN/AN/AN/AAug 10, 2017N/A
    Mar 31, 2017-$16.20-$20.70N/A+21.74%BeatN/AN/AN/AMay 11, 2017N/A
    Dec 31, 2016-$37.20-$27.00N/A-37.78%MissN/AN/AN/AMar 16, 2017N/A
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$0.23, after -$0.19 the year before. It was -$140.40 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$0.23N/A
    Dec 31, 2024-$0.19N/A
    Dec 31, 2023-$0.26N/A
    Dec 31, 2022-$0.38N/A
    Dec 31, 2021-$0.29N/A
    Dec 31, 2020-$0.36N/A
    Dec 31, 2019-$4.34N/A
    Dec 31, 2018-$60.00N/A
    Dec 31, 2017-$60.60N/A
    Dec 31, 2016-$140.40N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 5,100 words across 12 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20265,09812
    2026Q2Jun 30, 20264,3449
    2025Q4Dec 31, 20255,23510
    2025Q3Sep 30, 20254,25111
    2025Q2Jun 30, 20254,21810
    2025Q1Mar 31, 20253,53410
    2024Q4Dec 31, 20244,3419
    2024Q3Sep 30, 20243,0127

    2026Q3 Earnings Call

    Opening remarks

    Chris Clark VP of Communications Thank you, operator, and good morning, everyone. Joining me on today's call and webcast is Dr. Shankar Musunuri, Ocugen's Chairman, CEO, and Co-Founder, who will provide a business update and an overview of our clinical and operational progress. Rita Johnson-Greene, our Chief Financial Officer, is also on the call to provide a financial update for the quarter ended September 30th, 2026. Dr. Mohamed Genead, our Chief Medical Officer, Dr. Arun Upadhyay, our Chief Scientific Officer, and Abhi Gupta, Executive Vice President of Commercial and Business Development, will be available to answer questions following the presentation. This morning, we issued a press release covering our business and operational highlights for the third quarter of 2026. We encourage listeners to review the press release, which is available on our website at ocugen.com. A replay of this call, along with the slide presentation, will be available on the investors section of the Ocugen website. Before we begin, please note that certain statements made during today's discussion may be forward-looking in nature, including those related to our clinical development pipeline, regulatory timelines, commercialization strategy, international expansion, and financial information, and our anticipated cash runway. These statements reflect management's current expectations and are inherently subject to risks, uncertainties, and assumptions that may cause actual results to materially differ from those expressed or implied. We encourage you to review our filings with the Securities and Exchange Commission, including the risk factors detailed therein, for a more comprehensive understanding of these potential risks. Finally, Ocugen's quarterly report on Form 10-Q covering the third quarter of 2026 will be filed today. I will now turn the call over to Dr. Musunuri.

    Shankar Musunuri Chairman, CEO, and Co-Founder Thank you, Chris, and good morning, everyone. The third quarter was a quarter of execution for Ocugen. We now have all three of our late-stage modifier gene therapy programs in Phase III. We advanced our business development strategy, and we established a presence in Europe to support pre-commercial activities. With three Phase III programs underway, we're executing against a clear strategy to advance our pipeline and build our global presence through strategic partnerships to bring our therapies to patients around the world. Our modifier gene therapy platform remains the foundation of everything we do. Rather than targeting a single mutation, it is designed to address the underlying biology of complex retinal disease by restoring balance across multiple gene networks. The platform is gene agnostic, it is multifactorial, and it is designed to deliver durable benefit from a single one-time injection. That approach is what allows us to advance one platform across three major causes of blindness: geographic atrophy, retinitis pigmentosa, and Stargardt disease.

    Frequently Asked Questions About OCGN

    When is Ocugen's next earnings date?

    Ocugen's next earnings report is expected for Mar 2, 2027.

    Did OCGN beat earnings estimates last quarter?

    Ocugen reported EPS of -$0.06 for the quarter ended Sep 30, 2026, in line with the -$0.06 estimate.

    What EPS do analysts expect from OCGN next quarter?

    The consensus EPS estimate for Ocugen for the quarter ending Dec 31, 2026 is -$0.06 from 8 analysts, with estimates from -$0.07 to -$0.04.

    How often does OCGN beat earnings estimates?

    Ocugen beat the EPS estimate in 3 of the last 8 quarters, with an average surprise of -5.54%.